By: IPP Bureau
Last updated : August 08, 2024 3:28 pm
The company has seamlessly integrated the business acquired from Yash Pharma into Jagsonpal and are now confident of aligning the margins of the acquired business with that of Jagsonpal ahead of schedule
Jagsonpal Pharmaceuticals Limited has announced Q1 FY25 revenues of Rs. 61.4 crores, a 41% growth over Q4 FY24 and Operating EBITDA at Rs. 12.7 crores, margins at 20.6% for the quarter ended June 2024.
“Commenting on Company’s performance, Manish Gupta, Managing Director, Jagsonpal Pharmaceuticals Limited said “We started the year positively with a strong rebound in our business across all metrics. Our revenues and operating profits grew at 41% and 159% vis-à-vis Q4FY24 while operating margins stood at 20.6%. We seamlessly integrated the business acquired from Yash Pharma into Jagsonpal, and we are now confident of aligning the margins of the acquired business with that of Jagsonpal ahead of schedule. On the balance sheet side, our cash position remains robust at Rs. 77+ Cr and we have effectively funded the acquisition from cash generated over the last 2 years. With strong operational cash flows and the recently announced sale of Faridabad facility, we should be back at our cash position of Rs. 150+ crores by end of the year. With all our businesses tracking well, validating our strategic adjustments over the recent quarters, we stay on course to deliver 30%+ revenue growth with 20%+ operating margin for the full year.“